Voriconazole (injection)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Voriconazole (injection) is an antifungal triazole that is FDA approved for the treatment of invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. including fusarium solani, in patients intolerant of, or refractory to, other therapy. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Voriconazole (injection) FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Voriconazole in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Voriconazole in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Voriconazole (injection) FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Voriconazole in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Voriconazole in pediatric patients.
Contraindications
VFEND is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between VFEND (voriconazole) and other azole antifungal agents. Caution should be used when prescribing VFEND to patients with hypersensitivity to other azoles. Coadministration of terfenadine, astemizole, cisapride, pimozide or quinidine with VFEND is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes [see DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3)]. Coadministration of VFEND with sirolimus is contraindicated because VFEND significantly increases sirolimus concentrations [see DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3)]. Coadministration of VFEND with rifampin, carbamazepine and long-acting barbiturates is contraindicated because these drugs are likely to decrease plasma voriconazole concentrations significantly [see DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3)]. Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg q24h or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations [see DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3)]. Coadministration of VFEND with high-dose ritonavir (400 mg q12h) is contraindicated because ritonavir (400 mg q12h) significantly decreases plasma voriconazole concentrations. Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole [see DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3)]. Coadministration of VFEND with rifabutin is contraindicated since VFEND significantly increases rifabutin plasma concentrations and rifabutin also significantly decreases voriconazole plasma concentrations [see DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3)]. Coadministration of VFEND with ergot alkaloids (ergotamine and dihydroergotamine) is contraindicated because VFEND may increase the plasma concentration of ergot alkaloids, which may lead to ergotism [see DRUG INTERACTIONS (7), CLINICAL PHARMACOLOGY (12.3)]. Coadministration of VFEND with St. John's Wort is contraindicated because this herbal supplement may decrease voriconazole plasma concentration [see DRUG INTERACTIONS (7), and CLINICAL PHARMACOLOGY (12.3)].
Warnings
There is limited information regarding Voriconazole (injection) Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Voriconazole (injection) Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Voriconazole (injection) Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Voriconazole (injection) Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Voriconazole (injection) in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Voriconazole (injection) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Voriconazole (injection) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Voriconazole (injection) in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Voriconazole (injection) in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Voriconazole (injection) in geriatric settings.
Gender
There is no FDA guidance on the use of Voriconazole (injection) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Voriconazole (injection) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Voriconazole (injection) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Voriconazole (injection) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Voriconazole (injection) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Voriconazole (injection) in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Voriconazole (injection) Administration in the drug label.
Monitoring
There is limited information regarding Voriconazole (injection) Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Voriconazole (injection) and IV administrations.
Overdosage
There is limited information regarding Voriconazole (injection) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Voriconazole (injection) Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Voriconazole (injection) Mechanism of Action in the drug label.
Structure
There is limited information regarding Voriconazole (injection) Structure in the drug label.
Pharmacodynamics
There is limited information regarding Voriconazole (injection) Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Voriconazole (injection) Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Voriconazole (injection) Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Voriconazole (injection) Clinical Studies in the drug label.
How Supplied
There is limited information regarding Voriconazole (injection) How Supplied in the drug label.
Storage
There is limited information regarding Voriconazole (injection) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Voriconazole (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Voriconazole (injection) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Voriconazole (injection) Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Voriconazole interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Voriconazole (injection) Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Voriconazole (injection) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [4]
Overview
Category
Antifungal drug
US Brand Names
Vfend®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages